Tomoyuki Minowa

This study shows that in vitro-derived cDC1s resemble tumor-infiltrating DCs and that MHC-I and MHC-II antigen presentation by these cells is essential for effective cancer immunotherapy.

The paper constructs an integrated atlas of tumor-infiltrating dendritic cells across species and immunotherapy conditions, revealing conserved activation states and spatial reorganization in response to therapy.

This study identifies Bhlhe40 as a key regulator of T cell effector differentiation, showing distinct roles in CD4 and CD8 T cells for anti-PD-1 and anti-CTLA-4 therapies.